Haemacure Corporation (TSX:HAE) is a specialty bio-therapeutics company developing high-value human biological adhesives, hemostats and therapeutic proteins for commercialization.  Haemacure’s research and development effort is driven by its proprietary, high-yield plasma protein extraction technology to develop next-generation products, including surgical hemostats.

Haemacure’s lead product candidate, Hemaseel^_®HMN, is a human-derived fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first half of 2009. Haemacure’s second product candidate, Hemaseel^_®Thrombin^_, is a human active hemostat now in preclinical stage, and consists in human thrombin, a component of its fibrin sealant. 

Haemacure's product development activities will focus on the use of its fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medicine, skin graft fixation for burn injuries, surgical hemostasis and wound healing.  Haemacure has recently discovered eleven specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these specialty proteins and enzymes through partnerships with pharmaceutical and biotechnology companies.